NO20055306L - GITR ligand og GITR ligand relaterte molekyler og antistoffer og anvendelse derav - Google Patents

GITR ligand og GITR ligand relaterte molekyler og antistoffer og anvendelse derav

Info

Publication number
NO20055306L
NO20055306L NO20055306A NO20055306A NO20055306L NO 20055306 L NO20055306 L NO 20055306L NO 20055306 A NO20055306 A NO 20055306A NO 20055306 A NO20055306 A NO 20055306A NO 20055306 L NO20055306 L NO 20055306L
Authority
NO
Norway
Prior art keywords
gitrl
gitr
gitr ligand
present
ligand
Prior art date
Application number
NO20055306A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055306D0 (no
Inventor
Mary Collins
Deborah A Young
Beatriz M Carreno
Ethan Menahem Shevach
Rebecca Suzanne Mchugh
Matthew James Whitters
Michael Chapman Byrne
Padmalatha S Reddy
Geoffrey Laurence Stephens
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20055306D0 publication Critical patent/NO20055306D0/no
Publication of NO20055306L publication Critical patent/NO20055306L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
NO20055306A 2003-05-23 2005-11-10 GITR ligand og GITR ligand relaterte molekyler og antistoffer og anvendelse derav NO20055306L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47284403P 2003-05-23 2003-05-23
US54797504P 2004-02-26 2004-02-26
PCT/US2004/016381 WO2004107618A2 (en) 2003-05-23 2004-05-24 Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof

Publications (2)

Publication Number Publication Date
NO20055306D0 NO20055306D0 (no) 2005-11-10
NO20055306L true NO20055306L (no) 2006-01-30

Family

ID=33493329

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055306A NO20055306L (no) 2003-05-23 2005-11-10 GITR ligand og GITR ligand relaterte molekyler og antistoffer og anvendelse derav

Country Status (13)

Country Link
US (2) US7618632B2 (es)
EP (1) EP1631588A2 (es)
JP (2) JP4638876B2 (es)
KR (1) KR20060052681A (es)
AU (1) AU2004244626A1 (es)
BR (1) BRPI0410785A (es)
CA (1) CA2525717A1 (es)
CO (1) CO5680484A2 (es)
MX (1) MXPA05012475A (es)
NO (1) NO20055306L (es)
NZ (1) NZ543654A (es)
RU (1) RU2369636C2 (es)
WO (1) WO2004107618A2 (es)

Families Citing this family (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406867B1 (en) * 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US20060099171A1 (en) * 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
US7812135B2 (en) 2005-03-25 2010-10-12 Tolerrx, Inc. GITR-binding antibodies
WO2007133822A1 (en) * 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
KR100877978B1 (ko) * 2007-01-12 2009-01-12 가천의과학대학교 산학협력단 Ｃｄ８６ 분자가 넉 다운된 형질전환 돼지 혈관 내피세포주 및 이의 제조방법
US20080279851A1 (en) 2007-05-07 2008-11-13 Medlmmune, Llc Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP3124046B1 (en) * 2007-07-12 2019-12-25 GITR, Inc. Combination therapies employing gitr binding molecules
US20090136446A1 (en) * 2007-11-02 2009-05-28 Ludwig Institute For Cancer Research Ltd. Induction of regulatory t cell-resistant helper cd4+ t cells
CN102149820B (zh) 2008-09-12 2014-07-23 国立大学法人三重大学 能够表达外源gitr配体的细胞
KR20170091801A (ko) 2008-10-02 2017-08-09 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｃｄ86 길항제 다중-표적 결합 단백질
RU2595409C2 (ru) * 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
US9364534B2 (en) * 2009-09-15 2016-06-14 Csl Limited Treatment of neurological conditions
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
CN102309757B (zh) * 2010-07-09 2014-09-17 中国科学院上海巴斯德研究所 Foxp3及调节性ｔ细胞的调节因子及其应用
US8440195B2 (en) 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
EP2750690B1 (en) * 2011-11-15 2018-11-07 The Walter and Eliza Hall Institute of Medical Research Soluble mediator
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
WO2014145038A1 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
WO2015066413A1 (en) 2013-11-01 2015-05-07 Novartis Ag Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
EP3068435A1 (en) 2013-11-13 2016-09-21 Novartis AG Mtor inhibitors for enhancing the immune response
CN116478927A (zh) 2013-12-19 2023-07-25 诺华股份有限公司 人间皮素嵌合抗原受体及其用途
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
PL3122745T3 (pl) 2014-03-24 2019-08-30 Novartis Ag Monobaktamowe związki organiczne do leczenia zakażeń bakteryjnych
DK3129470T3 (da) 2014-04-07 2021-07-05 Novartis Ag Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor
EA201692458A1 (ru) 2014-05-28 2017-06-30 Агенус Инк. Анти-gitr антитела и способы их применения
KR102204937B1 (ko) 2014-06-06 2021-01-18 브리스톨-마이어스 스큅 컴퍼니 글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
BR112017001242A2 (pt) 2014-07-21 2017-12-05 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico a cd33
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
US10160726B2 (en) 2014-08-06 2018-12-25 Novartis Ag Quinolone derivatives as antibacterials
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
US20170281624A1 (en) 2014-09-13 2017-10-05 Novartis Ag Combination therapies of alk inhibitors
PL3194443T3 (pl) 2014-09-17 2022-01-31 Novartis Ag Nakierowywanie komórek cytotoksycznych za pośrednictwem receptorów chimerycznych do immunoterapii adoptywnej
EA201790737A1 (ru) 2014-10-03 2017-08-31 Новартис Аг Комбинированная терапия
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
MA41044A (fr) * 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
MY195743A (en) 2014-12-16 2023-02-08 Novartis Ag Isoxazole Hydroxamic Acid Compounds as LPXC Inhibitors
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
CA3197849A1 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
KR20170129802A (ko) 2015-03-10 2017-11-27 아두로 바이오테크, 인코포레이티드 ＂인터페론 유전자의 자극인자＂-의존적 신호전달을 활성화하는 조성물 및 방법
WO2016164580A1 (en) 2015-04-07 2016-10-13 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
HUE059218T2 (hu) 2015-04-08 2022-11-28 Novartis Ag CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
CA2982996A1 (en) 2015-04-17 2016-10-20 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EA201792497A1 (ru) 2015-06-03 2018-05-31 Бристол-Майерс Сквибб Компани Антитела к gitr для диагностики злокачественной опухоли
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
JP7146632B2 (ja) 2015-07-21 2022-10-04 ノバルティス アーゲー 免疫細胞の有効性および増大を改善する方法
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3344996A2 (en) 2015-09-03 2018-07-11 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
HRP20220436T1 (hr) 2015-11-03 2022-05-27 Janssen Biotech, Inc. Protutijela koja se specifično vežu na pd-1 i njihove uporabe
EP3377532B1 (en) 2015-11-19 2022-07-27 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
EP3383431A4 (en) * 2015-12-02 2019-08-28 Agenus Inc. ANTI-GITR ANTIBODIES AND METHOD OF USE THEREOF
EP3383430A4 (en) 2015-12-02 2019-12-18 Agenus Inc. ANTIBODIES AND METHOD FOR USE THEREOF
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
RU2018126297A (ru) 2015-12-18 2020-01-22 Новартис Аг Антитела, нацеленные на cd32b, и способы их применения
CN109069597A (zh) 2015-12-22 2018-12-21 诺华股份有限公司 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
CA3009852A1 (en) 2015-12-28 2017-07-06 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
KR20180100224A (ko) 2016-01-11 2018-09-07 노바르티스 아게 인간 인터루킨-2에 대한 면역-자극 인간화 단일클론 항체, 및 이의 융합 단백질
JOP20170045B1 (ar) 2016-02-19 2021-08-17 Novartis Ag مركبات بيريدون رباعية الحلقة كمضادات فيروسية
JP2019513347A (ja) 2016-03-04 2019-05-30 ノバルティス アーゲー 複数のキメラ抗原受容体（ｃａｒ）分子を発現する細胞およびその使用
EP3432927A4 (en) 2016-03-24 2019-11-20 Gensun Biopharma Inc. TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
ES2962269T3 (es) 2016-03-24 2024-03-18 Novartis Ag Análogos de nucleósidos alquinil como inhibidores del rinovirus humano
CA3027121A1 (en) 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
AU2017283768B2 (en) 2016-06-14 2019-05-23 Novartis Ag Crystalline form of (R)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
MX2018016227A (es) 2016-06-24 2019-07-08 Infinity Pharmaceuticals Inc Terapias de combinacion.
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
US10669344B2 (en) 2016-08-12 2020-06-02 Janssen Biotech, Inc. Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
WO2018031400A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
TW201811788A (zh) 2016-09-09 2018-04-01 瑞士商諾華公司 作為抗病毒劑之多環吡啶酮化合物
JP6908710B2 (ja) 2016-09-21 2021-07-28 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ケモカイン受容体ｃｃｒ４を標的にするキメラ抗原受容体（ｃａｒ）およびその使用
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
TW202340473A (zh) 2016-10-07 2023-10-16 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
TW201819380A (zh) 2016-10-18 2018-06-01 瑞士商諾華公司 作為抗病毒劑之稠合四環吡啶酮化合物
JOP20190100A1 (ar) * 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
KR20190104528A (ko) 2016-12-03 2019-09-10 주노 쎄러퓨티크스 인코퍼레이티드 Car-t 세포들 투여를 결정하는 방법
RS62456B1 (sr) 2016-12-22 2021-11-30 Amgen Inc Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
EP3367098A1 (en) * 2017-02-24 2018-08-29 CeMM - Forschungszentrum für Molekulare Medizin GmbH Methods for determining interaction between biological cells
WO2018187227A1 (en) 2017-04-03 2018-10-11 Concologie, Inc. Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111419A1 (es) 2017-04-27 2019-07-10 Novartis Ag Compuestos fusionados de indazol piridona como antivirales
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
UY37718A (es) 2017-05-05 2018-11-30 Novartis Ag 2-quinolinonas triciclicas como agentes antibacteriales
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
KR20200041834A (ko) 2017-06-01 2020-04-22 젠코어 인코포레이티드 Cd123 및 cd3에 결합하는 이중특이성 항체
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
WO2018223101A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
CN110719799A (zh) 2017-06-09 2020-01-21 俄勒冈州普罗维登斯健康与服务部 Cd39和cd103在鉴定用于癌症治疗的人肿瘤反应性t细胞中的应用
CN111050545A (zh) 2017-06-29 2020-04-21 朱诺治疗学股份有限公司 评估与免疫疗法相关的毒性的小鼠模型
CA3075046A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
SG11202003177RA (en) 2017-10-25 2020-05-28 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CN111902159A (zh) 2017-11-01 2020-11-06 朱诺治疗学股份有限公司 对b细胞成熟抗原（bcma）具有特异性的嵌合抗原受体
US20210079015A1 (en) 2017-11-17 2021-03-18 Novartis Ag Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
WO2019109053A1 (en) 2017-12-01 2019-06-06 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
US12006356B2 (en) 2017-12-15 2024-06-11 Juno Therapeutics, Inc. Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
US11234977B2 (en) 2017-12-20 2022-02-01 Novartis Ag Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
EP3759110A1 (en) 2018-02-28 2021-01-06 Novartis AG Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
WO2019184909A1 (zh) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA52496A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
KR20210016426A (ko) 2018-06-01 2021-02-15 노파르티스 아게 Cd123 및 cd3에 결합하는 이중특이적 항체의 투약
JP7360396B2 (ja) 2018-06-01 2023-10-12 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
JP7357644B2 (ja) 2018-06-11 2023-10-06 アムジエン・インコーポレーテツド がんを処置するためのｋｒａｓ ｇ１２ｃ阻害剤
WO2020050890A2 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP3806962A1 (en) 2018-06-13 2021-04-21 Novartis AG Bcma chimeric antigen receptors and uses thereof
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
CN112739717A (zh) 2018-06-29 2021-04-30 璟尚生物制药公司 三特异性拮抗剂
SG11202101779RA (en) 2018-08-30 2021-03-30 Hcw Biologics Inc Multi-chain chimeric polypeptides and uses thereof
CA3108951A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
US11672826B2 (en) 2018-08-30 2023-06-13 HCW Biologics, Inc. Methods of treating aging-related disorders
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
WO2020047452A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020051333A1 (en) 2018-09-07 2020-03-12 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
WO2020053654A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
WO2020069409A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
EP3856779A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd22 chimeric antigen receptor (car) therapies
MX2021003459A (es) 2018-09-29 2021-06-18 Novartis Ag Proceso de fabricacion de un compuesto para la inhibicion de la actividad de shp2.
TW202021981A (zh) 2018-11-01 2020-06-16 美商奇諾治療有限公司 G蛋白偶合受體c類第5群成員d（gprc5d）特異性嵌合抗原受體
MX2021005024A (es) 2018-11-01 2021-07-21 Juno Therapeutics Inc Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b.
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
US20220008465A1 (en) 2018-11-16 2022-01-13 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
PT3886875T (pt) 2018-11-30 2024-06-27 Juno Therapeutics Inc Métodos para tratamento utilizando terapia celular adotiva
EP3898592A1 (en) 2018-12-20 2021-10-27 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132649A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
TWI844602B (zh) 2018-12-20 2024-06-11 美商安進公司 Kif18a抑制劑
CA3123042A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
US20220096651A1 (en) 2019-01-29 2022-03-31 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
AU2020232616A1 (en) 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
RU2734432C1 (ru) * 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
MX2021014126A (es) 2019-05-21 2022-01-04 Amgen Inc Formas en estado solido.
CA3143035A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2020263312A1 (en) 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
JP2022542394A (ja) 2019-08-02 2022-10-03 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
MX2022001296A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
JP2022542967A (ja) 2019-08-02 2022-10-07 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
AU2020325115A1 (en) 2019-08-02 2022-03-17 Amgen Inc. Pyridine derivatives as KIF18A inhibitors
KR20220070005A (ko) 2019-09-26 2022-05-27 노파르티스 아게 항바이러스성 피라졸로피리디논 화합물
MX2022004656A (es) 2019-10-24 2022-05-25 Amgen Inc Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
TW202132314A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
CR20220240A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
CN114901662A (zh) 2019-11-08 2022-08-12 锐新医药公司 双环杂芳基化合物及其用途
US20230192682A1 (en) 2019-11-14 2023-06-22 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
BR112022009390A2 (pt) 2019-11-14 2022-08-09 Amgen Inc Síntese melhorada de composto inibidor de kras g12c
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
MX2022006365A (es) 2019-11-26 2022-06-22 Novartis Ag Receptores de antigeno quimerico cd19 y cd22 y usos de los mismos.
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
IL294484A (en) 2020-01-07 2022-09-01 Revolution Medicines Inc Dosage for shp2 inhibitor and methods for treating cancer
EP4104187A1 (en) 2020-02-14 2022-12-21 Novartis AG Method of predicting response to chimeric antigen receptor therapy
EP4106764A1 (en) * 2020-02-18 2022-12-28 Octagon Therapeutics Inc. Immune cell modulators
US20230174933A1 (en) 2020-02-27 2023-06-08 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2021171264A1 (en) 2020-02-28 2021-09-02 Novartis Ag Dosing of a bispecific antibody that binds cd123 and cd3
BR112022017156A2 (pt) 2020-03-06 2022-11-08 Regeneron Pharma Anticorpo isolado ou fragmento de ligação, molécula polinucleotídica isolada, vetor, célula hospedeira isolada, composição farmacêutica, método de tratamento de câncer, e, uso de um anticorpo
CN111218530B (zh) * 2020-03-19 2023-10-31 广西壮族自治区水产科学研究院 荧光定量pcr检测十足目虹彩病毒1的引物组及试剂盒
CN115916223A (zh) 2020-04-10 2023-04-04 朱诺治疗学股份有限公司 与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途
WO2021225159A1 (ja) * 2020-05-08 2021-11-11 国立大学法人三重大学 Ｇｉｔｒ結合性分子
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
BR112022025550A2 (pt) 2020-06-18 2023-03-07 Revolution Medicines Inc Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
TW202227460A (zh) 2020-09-15 2022-07-16 美商銳新醫藥公司 Ｒａｓ抑制劑
JP2023549504A (ja) 2020-11-13 2023-11-27 ノバルティス アーゲー キメラ抗原受容体（ｃａｒ）発現細胞との組合せ療法
US20240050432A1 (en) 2020-12-08 2024-02-15 Infinity Pharmaceuticals, Inc. Eganelisib for use in the treatment of pd-l1 negative cancer
US20240058349A1 (en) * 2020-12-18 2024-02-22 Northwestern University Pi3k inhibitors for protection against glucocorticoid-induced atrophy
JP2024501280A (ja) 2020-12-22 2024-01-11 キル・レガー・セラピューティクス・インコーポレーテッド Ｓｏｓ１阻害剤およびその使用
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ｒａｓ阻害剤及びその使用
CR20230570A (es) 2021-05-05 2024-01-22 Revolution Medicines Inc Inhibidores de ras
TW202309053A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
CA3218590A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
AU2022341239A1 (en) 2021-09-08 2024-03-21 Redona Therapeutics, Inc. Papd5 and/or papd7 inhibiting 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023154905A1 (en) 2022-02-14 2023-08-17 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024129778A2 (en) 2022-12-13 2024-06-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
CN116925206B (zh) * 2023-07-18 2024-04-23 湖南中晟全肽生物科技股份有限公司 Gitr相关的多肽及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5998171A (en) 1996-08-16 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human endokine alpha
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
GB9625074D0 (en) 1996-12-02 1997-01-22 Pharmacia & Upjohn Spa Receptor belonging to the TNF/NGF receptor family
JP4485049B2 (ja) * 1997-11-18 2010-06-16 ジェネンテック， インコーポレイテッド Ｄｎａ１９３５５ポリペプチドという腫瘍壊死因子相同体
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6077673A (en) 1998-03-31 2000-06-20 Clontech Laboratories, Inc. Mouse arrays and kits comprising the same
US20030133936A1 (en) 2001-07-12 2003-07-17 Byrne Michael Chapman CD25markers and uses thereof

Also Published As

Publication number Publication date
NZ543654A (en) 2009-05-31
WO2004107618A3 (en) 2005-02-10
MXPA05012475A (es) 2006-05-25
AU2004244626A1 (en) 2004-12-09
RU2369636C2 (ru) 2009-10-10
WO2004107618A2 (en) 2004-12-09
WO2004107618A9 (en) 2005-06-09
JP2011055833A (ja) 2011-03-24
JP2007515942A (ja) 2007-06-21
KR20060052681A (ko) 2006-05-19
CA2525717A1 (en) 2004-12-09
US20100080809A1 (en) 2010-04-01
US7618632B2 (en) 2009-11-17
JP4638876B2 (ja) 2011-02-23
NO20055306D0 (no) 2005-11-10
EP1631588A2 (en) 2006-03-08
RU2005140279A (ru) 2006-06-10
CO5680484A2 (es) 2006-09-29
US20050014224A1 (en) 2005-01-20
BRPI0410785A (pt) 2006-06-20

Similar Documents

Publication Publication Date Title
NO20055306L (no) GITR ligand og GITR ligand relaterte molekyler og antistoffer og anvendelse derav
Ravell et al. Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease
Li et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1
Kordinas et al. The telomere/telomerase system in chronic inflammatory diseases. Cause or effect?
Lazibat et al. Multiple sclerosis: new aspects of immunopathogenesis
Santegoets et al. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry
NO20074053L (no) Interleukin-17F antistoffer og andre IL-17F signaliseringsantagonister og anvendelser derav
Sticherling Systemic sclerosis–dermatological aspects. Part 1: pathogenesis, epidemiology, clinical findings
WO2007117444A3 (en) Protein detection by aptamers
WO2005054853A3 (en) Method for diagnosing diseases based on levels of anti-glycan antibodies
Falcone et al. Plasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis: possible correlation with clinical presentation
Lin et al. CCR6 deficiency impairs IgA production and dysregulates antimicrobial peptide production, altering the intestinal flora
Pan et al. Targeted discovery and validation of plasma biomarkers of Parkinson’s disease
Bystrom et al. Response to treatment with TNFα inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF+ T lymphocytes
WO2004092734A3 (en) Novel approach to molecular diagnosis of human papilloma virus-related diseases
BR0211835A (pt) método para avaliação e solução de compostos de teste, método para diagnóstico e prognóstico de distúrbios relacionados com gpcr, uso dos referidos compostos de teste e kit compreendendo os mesmos
Fanti et al. Circulating c-Met–expressing memory T cells define cardiac autoimmunity
Rihl et al. Identification of interleukin‐7 as a candidate disease mediator in spondylarthritis
Olczak et al. Elevated serum and urine levels of progranulin (PGRN) as a predictor of microglia activation in the early phase of traumatic brain injury: a further link with the development of neurodegenerative diseases
Magatti et al. Systemic immune response in young and elderly patients after traumatic brain injury
JP2017106915A (ja) Ｔ細胞の活性化を体液から捉える方法
Schulte‐Herbrüggen et al. Age‐dependent time course of cerebral brain‐derived neurotrophic factor, nerve growth factor, and neurotrophin‐3 in APP23 transgenic mice
Pavo et al. N‐terminal B‐type natriuretic peptide (NT‐proBNP) is associated with disease severity in multiple myeloma
Nunez et al. Prevalence and prognostic implications of active cytomegalovirus infection in patients with acute heart failure
Lushnikova et al. Patients with microscopic colitis have altered levels of inhibitory and stimulatory biomarkers in colon biopsies and sera compared to non-inflamed controls

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application